1. Introduction
Pilsicainide hydrochloride is classified into the class IC antiarrhythmic drug group 1). Pilsicainide increases the PQ interval, QRS width and QTc, and its serum concentration correlates well with the rate of PQ interval prolongation2). Pilsicainide was developed in Japan and launched in 1991, and until not long ago, it was one of the most frequently used arrhythmic drugs in Japan. We report a case of a patient who took a large dose of pilsicainide in a suicide attempt.